Optimising Treatments for Faecal Incontinence

Sponsor
London North West Healthcare NHS Trust (Other)
Overall Status
Completed
CT.gov ID
NCT04273009
Collaborator
(none)
50
2
20.9

Study Details

Study Description

Brief Summary

The purpose of the study is to directly compare two medical treatments for faecal incontinence: Renew™ Anal Insert and Percutaneous Tibial Nerve Stimulation (PTNS) for a period of 12 weeks. Both are routinely used in our practice.

Condition or Disease Intervention/Treatment Phase
  • Device: Renew VS PTNS
N/A

Detailed Description

The Renew™ anal insert is a new single-use anal device, CE marked and widely used in the UK and Europe. It is indicated for the management of faecal incontinence and designed to seal and prevent the involuntary passage of stool from the rectum. The device is intended for self-insertion aided by a fingertip applicator.

Percutaneous tibial nerve stimulation (PTNS) is a form of electrical stimulation that offers a simple minimally invasive outpatient treatment for faecal incontinence. A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points. The treatment requires 12 outpatients sessions that are 30 minutes long each time and the treatment may be repeated.

Patients will be randomly allocated to either receive PTNS therapy or the Renew™ device. This will be done by the investigators randomly selecting a sealed envelope that is not see-through from a large number of identical envelopes. Each of these envelopes will contain either the word PTNS or the word Renew, which will then determine patients' treatment. There will be an equal number of PTNS and Renew envelopes to make this decision truly random. The principal investigator of this study will not know which treatment patients have been allocated to until after the study is complete. Patients who wish to change treatment before the study ends will be withdrawn from the study.

During the study the investigators will ask patients to complete some standard questionnaires that are normally used to score the degree of the incontinence and to assess bowel symptoms.: These will be completed at the hospital during the standard clinic consultation, both before patients start the treatment and after having completed the treatment course.

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Patients who have completed the treatment can switch to the other treatment offered.Patients who have completed the treatment can switch to the other treatment offered.
Masking:
Double (Participant, Investigator)
Masking Description:
Both participants and first investigator will be masked from the actual treatment.
Primary Purpose:
Treatment
Official Title:
Percutaneous Tibial Nerve Stimulation With the Renew Anal Plug Device for the Treatment of Faecal Incontinence
Actual Study Start Date :
Dec 15, 2016
Actual Primary Completion Date :
Aug 11, 2018
Actual Study Completion Date :
Sep 11, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Renew Anal Insert

The device is intended for self-insertion through the anal canal aided by a fingertip applicator.

Device: Renew VS PTNS
These will be prescribed and applied as described above.

Active Comparator: Percutaneous tibial nerve stimulation

A fine needle is inserted next to the tibial nerve above the ankle, a ground pad is attached to the heel and electric current just strong enough to cause minor tingling is passed between these two points.

Device: Renew VS PTNS
These will be prescribed and applied as described above.

Outcome Measures

Primary Outcome Measures

  1. Renew vs PTNS treatment [3 months]

    A consecutive two weeks bowel diaries at 3 months follow up Use of PTNS or RENEW Frequency of episodes of faecal incontinence

Secondary Outcome Measures

  1. Pain [3 months]

    Five-point visual analog scale (VAS) from 0 to 10

  2. Severity of incontinence [3 months]

    This will be measured using a single validated outcome measure valued in score (St Mark's faecal incontinence score): this measure in a grade from 0 to 4, the number of episodes of incontinence to solid stools, the number of episodes of incontinence to liquid stools, the number of episodes of incontinence to flatus (gas). It also measures in a grade from 0 to 4 the frequency of the use of pads and the frequency of use constipating medicines. The sum of the numbers will give a final score which will be used as method to measure the severity of incontinence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Passive or mixed faecal incontinence.

  • Minimum two or more episodes of faecal incontinence per week as assessed by prospectively collected bowel diaries.

  • Failed biofeedback, pelvic floor physiotherapy or other medical management.

  • Able to self- administer the Renew™ Anal Insert.

  • Competent and willing to fill in questionnaires and attend clinics throughout the study.

  • Patient must be able to comprehend and informed consent prior to enrolment in the study.

Exclusion Criteria:
  • Pregnancy.

  • Inability to given informed consent.

  • Perianal sepsis.

  • Rectal bleeding.

  • Inflammatory bowel disease/ Proctitis.

  • Rectal prolapse.

  • Third or fourth-degree hemorrhoids.

  • Anal stricture.

  • Anal or Recto-vaginal fistula.

  • Rectal surgery in the past 3 months.

  • Known allergy to Silicone.

  • Patients who are mentally or physically unable to comply with the protocol of the study.

  • The presence of any other medical condition which, in the opinion of the Chief Investigator, deems the patient unsuitable for participation in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • London North West Healthcare NHS Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
London North West Healthcare NHS Trust
ClinicalTrials.gov Identifier:
NCT04273009
Other Study ID Numbers:
  • 16/LO/1821
First Posted:
Feb 17, 2020
Last Update Posted:
Feb 17, 2020
Last Verified:
Feb 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 17, 2020